Can Tarceva cure lung cancer?

Can Tarceva cure lung cancer?

Tarceva (erlotinib) is widely used in the management of EGFR + non-small cell lung cancer (NSCLC) and clinical studies suggests it improves survival in early stage disease, as part of initial treatment for stage IV NSCLC, as maintenance therapy and in select individuals with recurrent disease.

What are the odds of surviving stage 4 lung cancer?

According to the National Cancer Institute (NCI), 57 percent of lung and bronchus cancer is diagnosed at stage 4….What are the survival rates for stage 4 lung cancer?

Stage 5-year survival rate
Distant (stage 4) small cell lung cancer 3 percent
All stages combined for small cell lung cancer 7 percent

How is Tarceva used to treat lung cancer?

Tarceva May Improve Survival From Lung Cancer. Study Shows Drug Has Benefits as Initial Treatment of Some Advanced Lung Cancers. From the WebMD Archives. Oct. 11, 2010 – Patients whose advanced lung cancers bear the EGFR mutation survive two to three times longer if given initial treatment with Tarceva, a Chinese study suggests.

What’s the average life expectancy of Tarceva patients?

Median progression-free survival — that is, time until the cancer got worse — was only 4.6 months for standard chemotherapy but was 13.1 months for patients taking Tarceva. Moreover, patients taking Tarceva suffered far fewer side effects of therapy than those on standard chemo.

Are there any side effects to taking Tarceva?

Moreover, patients taking Tarceva suffered far fewer side effects of therapy than those on standard chemo. Zhou reported the study findings at this week’s meeting of the European Society for Medical Oncology in Milan, Italy.

Are there any new treatments for lung cancer?

With the development of new and promising lung cancer treatments, more people may have a chance of achieving remission than ever before. What does lung cancer remission mean? Remission can mean different things when used to describe your response to your cancer treatment.

What are the benefits of Tarceva for lung cancer patients?

Tarceva has been shown to extend the progression-free survival time and improve the quality of life of many advanced lung cancer patients, especially for those who with positive EGFR. However, the information regarding its long-term survival benefit is still very limited.

When to use Tarceva in combination with gemcitabine?

1.2 Pancreatic Cancer TARCEVA in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer [see Clinical Studies (14.5)].

What is the overall survival probability for Tarceva?

Most reports from clinical trials on TKI (tarceva or irresa) have focused on progression free survival probability (PFS). The median time of PFS (the time half of the patients have progressed) for positive EGFR on TKI ranged from 9 to 15 months. Some reports did include the overall survival probability (OS).

When to take Tarceva for pancreatic cancer?

2.3 Recommended Dose – Pancreatic Cancer The recommended daily dose of TARCEVA for pancreatic cancer is 100 mg taken once daily in combination with gemcitabine. Take TARCEVA on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food.